https://www.prnewswire.com/news-releases/ideaya-reports-positive-interim-phase-2-clinical-results-for-darovasertib-and-crizotinib-synthetic-lethal-combination-in-metastatic-uveal-melanoma-301621601.html
0
0
9/11/22 at 9:00pm
Organization
PRNewswire
Authors
Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patients...
Create an account
or login to join the discussion